Fermenta Biotech Q1 FY27 Results: Profit Declines, Revenue Steady
Fermenta Biotech reported Q1 FY27 results with standalone revenue at ₹11,183.93 lakh and profit before tax at ₹2,014.58 lakh. Consolidated revenue was ₹12,182.12 lakh and profit before tax was ₹1,469.15 lakh. The results were approved on August 11, 2026.
The financial results show a decrease in profitability, which could impact investor sentiment and the company's stock performance. However, the revenue remained relatively steady, and the auditor's report was unmodified, suggesting the decline might be manageable.
The company reported a decline in both standalone and consolidated profits for the quarter ended June 30, 2026, compared to the same period in the previous year, indicating a negative financial performance.
Fermenta Biotech Limited announced its Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The Board of Directors approved these results at a meeting held on August 11, 2026.
The company reported a standalone revenue from operations of ₹11,183.93 lakh for the quarter, a slight decrease from ₹11,901.87 lakh in the same period last year. Profit before tax stood at ₹2,014.58 lakh, down from ₹2,271.92 lakh year-on-year.
On a consolidated basis, revenue from operations was ₹12,182.12 lakh, compared to ₹13,626.27 lakh in the prior year's quarter. Consolidated profit before tax was ₹1,469.15 lakh, a decrease from ₹2,808.71 lakh in the corresponding quarter of the previous year.
The limited review reports on the financial results were issued by M/s. SRBC & Co. LLP, Chartered Accountants, with an unmodified opinion.
What to do with a filing like this
Fermenta Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fermenta Biotech Limited. Read the original for the full detail.